 |
JOURNAL TOOLS |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Reprints |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
CASE REPORTS
Gazzetta Medica Italiana Archivio per le Scienze Mediche 2008 August;167(4):185-90
Copyright © 2008 EDIZIONI MINERVA MEDICA
language: Italian
Carbamazepine-induced interstitial lung disease: case report
Guarino C. 1, Pecoraro A. 1, De Rosa N. 2, Del Giudice G. 1, Pedicelli I. 1, Mascitti S. 1, La Cerra G. 1, Marzo C. 1
1 Dipartimento di Scienze Cardio-Toraciche Seconda Università degli Studi di Napoli A.O. Monadi, Napoli, Italia 2 Servizio di Istologia e Anatomia Patologica A.O. Monadi, Napoli, Italia
Drug-induced interstitial lung disease (DI-ILD) is the most frequent manifestation of iatrogenic lung damage. Carbamazepine is used in the treatment of epilepsy, neuropathic pain, and in lithium-resistant bipolar disorder. The case report describes a 48-year-old man, non-smoker, with a remote history of arterial hypertension, multinodular goiter, and petit mal epilepsy, for which he was receiving phenobarbitol 200 mg/die and carbamazepine 200 mg/die. The patient reported the onset about one year earlier of dry cough and dyspnea on exertion. Findings of clinical, functional, radiologic and anatomopathologic studies were attributable to DI-ILD. Suspension of carbamazepine and steroid treatment led to clinical, radiologic, and functional improvement.